A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
Study Details
Study Description
Brief Summary
A Clinical Study to learn if SEP-363856 has physical dependence in adults with schizophrenia. This study will be held in approximately 6 study sites in the United States. It will be accepting male and female participants age 18 years to 65 years. Participation will be up to approximately10 weeks.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
This is a double-blind, placebo-controlled, randomized withdrawal study comparing abrupt discontinuation of SEP-363856 (SEP-363856 switched to placebo) to continuous SEP-363856 treatment in male and female adult subjects with schizophrenia.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: SEP-363856
|
Drug: SEP-363856
SEP-363856 Tablet
|
| Placebo Comparator: Placebo
|
Drug: Placebo
Placebo Tablet
|
Outcome Measures
Primary Outcome Measures
- Maximum change from the steady-state baseline (CSSBmax) in the total score of the 20 item Physician Withdrawal Checklist (PWC-20) during the 7-day Randomized Withdrawal Period [up to10 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria: (this list is not all inclusive)
-
Male or female subject between 18 and 65 years of age (inclusive) at the time of informed consent.
-
Subject meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a primary diagnosis of schizophrenia as established by clinical interview (using the DSM-5 as a reference and confirmed using the Structured Clinical Interview for DSM-5, Clinical Trials Version [SCID-CT]).
-
Subject must have a Clinical Global Impression-Severity Scale (CGI-S) score ≤ 4 (normal to moderately ill) at Screening and Day 1.
-
Subject must have a PANSS total score ≤ 80 at Screening and a score of ≤ 4 on the following PANSS items at Screening: P7 (hostility) and G8 (uncooperativeness).
-
Subject has been taking an antipsychotic for at least 6 weeks prior to Screening and has had no change in antipsychotic medication(s) (minor dose adjustments for tolerability purposes may be permitted) for at least 6 weeks prior to Screening.
Exclusion Criteria: (this list is not all inclusive)
-
Subject has a DSM-5 diagnosis or presence of symptoms consistent with a current DSM-5 diagnosis other than schizophrenia.
-
Subject has attempted suicide within 6 months prior to Screening.
-
Subject answers "yes" to "Suicidal Ideation" Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening (ie, in the past 1 month) or at any subsequent C-SSRS assessment prior to dosing (ie, since last visit).
-
Subject is at significant risk of harming him/herself or others (passive or active) according to the Investigator's judgment.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Sunovion
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SEP361-121